Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydroxyzine Pamoate

FDA-approved product (capsule, oral), marketed as Atarax, Hydroxyzine, Hydroxyzine Hydrochloride and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Hydroxyzine Pamoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety
  • Anxiety disorder
  • Neurotic disorder
  • Pruritus
  • Skin disease
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Diphenylmethane derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydroxyzine Pamoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydroxyzine Pamoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

    NCT02738008 · start 2016-03

    Registered record
    Registry ID
    NCT02738008
    Conditions
    Hepatitis B
    Interventions
    ARC-520 Injection; entecavir; tenofovir; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-03
    Completion
    2016-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionARC-520 Injection; entecavir; tenofovir; antihistamine
    PhasePhase 2
    Registry statusTerminated

  • Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

    NCT02613910 · start 2015-12-23

    Registered record
    Registry ID
    NCT02613910
    Conditions
    Pemphigus
    Interventions
    Ofatumumab; Acetaminophen/paracetamol; Antihistamine (cetirizine or equivalent); Prednisone/Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-12-23
    Completion
    2016-03-23
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPemphigus
    InterventionOfatumumab; Acetaminophen/paracetamol; Antihistamine (cetirizine or equivalent); Prednisone/Prednisolone
    PhasePhase 3
    Registry statusTerminated

  • Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

    NCT02577029 · start 2015-12

    Registered record
    Registry ID
    NCT02577029
    Conditions
    Hepatitis B; Hepatitis D
    Interventions
    ARC-520; entecavir; pegylated interferon alpha 2a; tenofovir disoproxil; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-12
    Completion
    2016-12
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; Hepatitis D
    InterventionARC-520; entecavir; pegylated interferon alpha 2a; tenofovir disoproxil +1 more
    PhasePhase 2
    Registry statusTerminated

  • Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.

    NCT03047278 · start 2015-11-01

    Registered record
    Registry ID
    NCT03047278
    Conditions
    Neuropathic Pain; Type 2 Diabetes Mellitus; Diabetic Neuropathy, Painful
    Interventions
    Serial Blood Samples; Serial Urine Samples; Gabapentin 300 mg; Cetirizine Hydrochloride 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-11-01
    Completion
    2019-07-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuropathic Pain; Type 2 Diabetes Mellitus; Diabetic Neuropathy, Painful
    InterventionSerial Blood Samples; Serial Urine Samples; Gabapentin 300 mg; Cetirizine Hydrochloride 10 mg
    PhasePhase 4
    Registry statusCompleted

  • Hydroxyzine and Risk of Prolongation of QT Interval

    NCT02814981 · start 2015-11

    Registered record
    Registry ID
    NCT02814981
    Conditions
    Hydroxyzine; Long QT Syndrome
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2015-11
    Completion
    2017-10
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHydroxyzine; Long QT Syndrome
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

    NCT02604199 · start 2015-09

    Registered record
    Registry ID
    NCT02604199
    Conditions
    Hepatitis B
    Interventions
    ARC-520 Injection; placebo; entecavir; tenofovir; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2017-01
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionARC-520 Injection; placebo; entecavir; tenofovir +1 more
    PhasePhase 2
    Registry statusTerminated

  • Neuromyelitis Optica (NMO) & Cetirizine

    NCT02865018 · start 2014-04

    Registered record
    Registry ID
    NCT02865018
    Conditions
    Neuromyelitis Optica
    Interventions
    cetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromyelitis Optica
    Interventioncetirizine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

    NCT02023164 · start 2013-07

    Registered record
    Registry ID
    NCT02023164
    Conditions
    Acute Urticaria
    Interventions
    JDP-205 Injection; Diphenhydramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Urticaria
    InterventionJDP-205 Injection; Diphenhydramine
    PhasePhase 3
    Registry statusCompleted

  • Interaction Between Drug and Placebo Effect:Randomized Placebo Controlled Trials May Not be Accurate in Determining Drug Effect Size

    NCT01501591 · start 2012-11

    Registered record
    Registry ID
    NCT01501591
    Conditions
    Placebo Effect; Placebo Drug Interaction
    Interventions
    Hydroxizine; Placebo; hydroxyzine/placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-11
    Completion
    2015-10
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlacebo Effect; Placebo Drug Interaction
    InterventionHydroxizine; Placebo; hydroxyzine/placebo
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetic Study of Levocetirizine Oral Solution

    NCT01622283 · start 2012-05-02

    Registered record
    Registry ID
    NCT01622283
    Conditions
    Rhinitis, Allergic, Perennial and Seasonal
    Interventions
    Levocetirizine; Cetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-05-02
    Completion
    2012-06-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial and Seasonal
    InterventionLevocetirizine; Cetirizine
    PhasePhase 1
    Registry statusCompleted

  • Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving

    NCT01496911 · start 2012-04

    Registered record
    Registry ID
    NCT01496911
    Conditions
    Healthy Volunteers
    Interventions
    Levocetirizine; Hydroxyzine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionLevocetirizine; Hydroxyzine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks

    NCT01557712 · start 2012-03

    Registered record
    Registry ID
    NCT01557712
    Conditions
    Major Depressive Disorder
    Interventions
    ketamine venlafaxine; Venlafaxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2017-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    Interventionketamine venlafaxine; Venlafaxine
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

    NCT01484119 · start 2011-12

    Registered record
    Registry ID
    NCT01484119
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    ACT-129968; Placebo; Cetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2012-03
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionACT-129968; Placebo; Cetirizine
    PhasePhase 3
    Registry statusCompleted

  • Study of Bronchodilation Effects of Cetirizine

    NCT01781507 · start 2011-06

    Registered record
    Registry ID
    NCT01781507
    Conditions
    Allergic Rhinitis; Asthma
    Interventions
    Cetirizine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-06
    Completion
    2011-12
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Asthma
    InterventionCetirizine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Rhinitis, Cognition and Driving Performance

    NCT01318681 · start 2011-01

    Registered record
    Registry ID
    NCT01318681
    Conditions
    Seasonal Allergic Rhinitis; Driving Ability; Cognition
    Interventions
    cetirizine 10 mg; fluticasone furoate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-01
    Completion
    2012-10
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis; Driving Ability; Cognition
    Interventioncetirizine 10 mg; fluticasone furoate; placebo
    PhaseNot applicable
    Registry statusCompleted